Three psychedelic drugs show distinct brain effects in rat scans
How brain scans revealed varying neural responses
Researchers at the University of Southern Denmark used brain imaging to compare how three psychedelic compounds influence neural activity in rats. The study, published recently, focused on substances that activate the serotonin 2A receptor, a key target for hallucinogenic effects. By administering LSD, psilocybin, and DMT separately, the team observed variations in brain connectivity and metabolic patterns across different regions. These differences suggest that despite sharing a common mechanism, each drug produces a unique neurological signature. The findings contribute to ongoing efforts to understand how psychedelics might be tailored for specific therapeutic applications.
The researchers employed positron emission tomography (PET) scans using a tracer that binds to the 5-HT2A receptor, allowing them to measure receptor occupancy and downstream effects. Rats were scanned after receiving equivalent doses of each psychedelic, with control groups given saline. Results showed that LSD produced the most widespread and prolonged changes in cortical activity, particularly in areas linked to perception and cognition. Psilocybin induced moderate but consistent shifts in limbic regions, associated with emotion and memory. DMT, meanwhile, triggered intense but short-lived activation in visual and sensory cortices. These patterns were quantified using standardized uptake value ratios, confirming statistically significant differences between compounds.
Why do similar drugs produce different brain effects?
Although all three substances primarily act as agonists at the 5-HT2A receptor, their distinct chemical structures influence how they interact with the receptor over time. LSD binds more tightly and dissociates slowly, leading to longer-lasting effects. Psilocybin, which converts to psilocin in the body, has a moderate binding affinity and duration. DMT is rapidly metabolized, resulting in a brief but intense experience. The study suggests that these pharmacokinetic differences—how the body absorbs, distributes, and eliminates each compound—translate into divergent neural dynamics. Researchers noted that receptor downregulation and secondary signaling pathways may also contribute to the observed variations.
What was the main goal of the rat brain scan study? The study aimed to compare how three psychedelic drugs—LSD, psilocybin, and DMT—affect brain activity despite sharing a common target receptor, to better understand their differing effects.
Frequently Asked Questions
How did researchers measure brain activity in the rats? They used PET scans with a specialized tracer to track 5-HT2A receptor engagement and metabolic changes in the brain after administering each drug.
Could these findings influence future psychedelic therapy? Yes, understanding the unique brain profiles of each compound may help clinicians select or design psychedelics suited to specific mental health conditions.